Natera, Inc. (NASDAQ:NTRA) Position Trimmed by Harvest Fund Management Co. Ltd

Harvest Fund Management Co. Ltd lessened its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 33.0% during the 4th quarter, HoldingsChannel reports. The fund owned 5,205 shares of the medical research company’s stock after selling 2,569 shares during the period. Harvest Fund Management Co. Ltd’s holdings in Natera were worth $780,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Blue Trust Inc. grew its stake in shares of Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock valued at $30,000 after buying an additional 97 shares in the last quarter. Versant Capital Management Inc grew its stake in shares of Natera by 345.8% in the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after buying an additional 166 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Natera by 372.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock valued at $52,000 after buying an additional 261 shares in the last quarter. Principal Securities Inc. grew its stake in shares of Natera by 20.7% in the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock valued at $54,000 after buying an additional 59 shares in the last quarter. Finally, True Wealth Design LLC bought a new stake in shares of Natera in the 3rd quarter valued at approximately $57,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Insider Activity at Natera

In related news, insider Solomon Moshkevich sold 6,000 shares of the company’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $143.29, for a total value of $859,740.00. Following the completion of the transaction, the insider now directly owns 143,768 shares in the company, valued at approximately $20,600,516.72. This represents a 4.01 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Michael Burkes Brophy sold 792 shares of the company’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $146.04, for a total value of $115,663.68. Following the completion of the transaction, the chief financial officer now owns 71,869 shares of the company’s stock, valued at $10,495,748.76. The trade was a 1.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 307,466 shares of company stock worth $49,047,655. 7.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. StockNews.com raised Natera from a “sell” rating to a “hold” rating in a research note on Wednesday. JPMorgan Chase & Co. upped their target price on Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. BTIG Research reaffirmed a “buy” rating on shares of Natera in a research report on Friday, February 28th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $180.00 target price on shares of Natera in a research report on Wednesday, February 26th. Finally, Sanford C. Bernstein upped their target price on Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, January 10th. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $178.12.

Natera Stock Down 0.8 %

Shares of NTRA stock opened at $149.63 on Friday. The stock has a 50 day moving average of $161.71 and a 200-day moving average of $149.27. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The firm has a market cap of $20.23 billion, a PE ratio of -85.02 and a beta of 1.80. Natera, Inc. has a 12 month low of $83.13 and a 12 month high of $183.00.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.01. The business had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. On average, equities analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.